Electrophysiological effects of dofetilide in an in vitro model of 'border zone' between normal and ischemic/reperfused myocardium

Circulation

Volumn 101, Issue 1, 2000, Pages 86-93

  Rouet, René ^a   Picard, Sandra ^a   Libersa, Christian ^b   Ghadanfar, Mathieu ^c   Alabaster, Colin ^c   Gérard, Jean Louis ^a  

^a Universite   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Antiarrhythmia agents; Ischemia; Myocardium; Reperfusion

Indexed keywords

DOFETILIDE;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GUINEA PIG; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART MUSCLE REPERFUSION; HEART REPOLARIZATION; HEART STIMULATION; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034602823     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.1.86     Document Type: Article

References (41)

1. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 1992; 262:809-817.
2. Yang T, Tande PM, Refsum H. Electromechanical action of dofetilide and d-sotalol during simulated metabolic acidosis in isolated guinea pig ventricular muscle. J Cardiovasc Pharmacol. 1992;20:889-894.
3. Gjini V, Korth M, Schreieck J, Weyerbrock S, Schömig A, Schmitt C. Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies. J Cardiovasc Pharmacol. 1996;28:314-320.
4. Pallandi RT, Lovell NH, Campbell TJ. Class III antiarrhythmic effects of dofetilide in rabbit atrial myocardium. J Cardiovasc Pharmacol Ther. 1996;1:229-234.
5. Ishii M, Kamiya J, Hashimoto K. Cellular electrophysiological effects of MS-551, a new class III antiarrhythmic agent. Drug Dev Res. 1995;35: 61-68.
6. D'Alonzo AJ, Sewter JC, Darbenzio RB, Hess TA. Effects of dofetilide on electrical dispersion and arrhythmias in post-infarcted anesthetized dogs. Basic Res Cardiol. 1995;90:424-434.
7. Lu HR, Remeysen P, Declerck F. Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs. J Cardiovasc Pharmacol. 1995;26:132-136.
8. Gemmill JD, Howie CA, Meredith PA, Kelman AW, Rasmussen HS, Hillis WS, Elliott HL. A dose-ranging study of UK-68,798, a novel class III antiarrhythmic agent, in normal volunteers. Br J Clin Pharmacol. 1991;32:429-432.
9. Démolis JL, Funck-Brentano C, Ropers J, Ghadanfar M, Nichols DJ, Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation. 1996;94: 1592-1599.
10. Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol. 1992;69:513-517.
11. Montera M, Schmitt C. Recording of transmembrane action potentials in chronic ischemic heart disease and dilated cardiomyopathy and the effects of the new class III antiarrhythmic agents d-sotalol and dofetilide. J Cardiovasc Pharmacol. 1996;27:571-577.
12. Black SC, Chi L, Mu DX, Lucchesi BR. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J Pharmacol Exp Ther. 1991;258:416-423.
13. Andersen HR, Wiggers H, Knudsen LL, Simonsen I, Thomsen PEB, Christiansen N. Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia: a randomised study in pigs. Cardiovasc Res. 1994;28:1635-1640.
14. Gout B, Nichols AJ, Feuerstein GZ, Bril A. Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia. J Cardiovasc Pharmacol. 1995;26:636-644.
15. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter, J Am Coll Cardiol. 1997;29:385-390.
16. Bashir Y, Thomsen PE, Kingma JH, Moller M, Wong C, Cobbe S, Jordaens L, Campbell R, Rasmussen H, Camm AJ. Electrophysiologic profile and efficacy on intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol. 1995;76:1040-1044.
17. Brachmann J, Haverkamp W, Johns J, Zehender M, Kingman HG, Wiecha J. The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia. Circulation. 1995;86(suppl I):I-265. Abstract.
18. Hondeghem L, Snyders D. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686-690.
19. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol. 1995;6:920-936.
20. Lipka L; Dizon J; Reiffel J. Desired mechanisms of drugs for ventricular arrhythmia: class III antiarrhythmic agents. Am Heart J. 1995;130: 632-640.
21. Cobbe SM. Class III antiarrhythmics: put to the SWORD? Heart. 1996; 75:111-113.
22. Rouet R, Adamantidis M, Honore E, Dupuis B. In vitro abnormal repetitive responses in guinea pig ventricular myocardium exposed to combined hypoxia, hyperkalemia and acidosis. J Appl Cardiol. 1989;4: 19-29.
23. Picard S, Rouet R, Monti F, Puddu PE, Ducouret P, Flais F, Gérard JL. Proarrhythmic effects of dl-and d-sotalol on the "border zone" between normal and ischemic regions of isolated ventricular myocardium and antiarrhythmic effects on reperfusion. J Cardiovasc Pharmacol. 1998;31: 126-139.
24. Pasnani JS, Ferrier GR. Pro-and anti-arrhythmic effects of d-sotalol and dl-sotalol in an isolated tissue model of ischemia and reperfusion. J Pharmacol Exp Ther. 1994;271:184-192.
25. Janse MJ, Cinca J, Morena H, Fiolet JW, Kleber AG, de Vries GP, Becker AE, Durrer D. The "border zone" in myocardial ischemia: an electrophysiological, metabolic and histochemical correlation in the pig heart. Circ Res. 1979;44:576-588.
26. El-Sherif N, Mehra R, Gough WB, Zeiler RH. Ventricular activation patterns of spontaneous and induced ventricular rhythms in canine 1-day-old myocardial infarctions: evidence for local and reentrant mechanisms. Circ Res. 1981;51:152-166.
27. Puddu PE, Rouet R. Are different pharmacokinetic properties of lidocaine versus propafenone in normal as compared to ischemic myocardium responsible for different electrophysiologic effects which help preventing arrhythmias? Cardiologia. 1988;33:459-462.
28. Bélichard P, Pruneau D, Rouet R, Salzmann JL. Electrophysiological responses of hypertrophied rat myocardium to combined hypoxia, hyperkalemia and acidosis. J Cardiovasc Pharmacol. 1991;17(suppl 2):S141-S145.
29. Schiariti M, Puddu PE, Rouet R. Multivariate prediction of spontaneous repetitive responses in ventricular myocardium exposed in vitro to simulated ischemic conditions. Int J Cardiol. 1994;45:9-22.
30. Morena H, Janse MJ, Fiolet JWT, Krieger WJG, Crijns H, Durrer D. Comparison of the effects of regional ischemia, hypoxia, hyperkalemia and acidosis on intracellular and extracellular potentials and metabolism in isolated porcine heart. Circ Res. 1980;46:634-646.
31. Kr blockers dofetilide, D-sotalol, E-4031 and MK-499. J Cardiovasc Pharmacol. 1994;24:199-208.
32. Kr: implications for torsades de pointes and reverse use-dependence. Circulation. 1996;93:407-411.
33. Coetzee WA. ATP-sensitive potassium channels and myocardial ischemia: why do they open? Cardiovasc Drugs Ther. 1992;6:201-208.
34. West PD, Bursill JA, Wyse KR, Martin DK, Campbell TJ. Effect of dofetilide and d-sotalol on the ATP-sensitive potassium channel of rabbit ventricular myocytes. J Cardiovasc Pharmacol Ther. 1996;1:307-312.
35. Yuan S, Wohlfart B, Olsson SB, Blomström-Lundqvist C. The dispersion of repolarization in patients with ventricular tachycardia. Eur Heart J. 1995;16:68-76.
36. Janse MJ, Van Capelle JL, Morsink H, Kleber AG, Wilms-Schopman F, Cardinal R, d'Alnoncourt CN, Durrer D. Flow of "injury" current and patterns of excitation during early ventricular arrhythmias in acute regional myocardial ischemia in isolated porcine and canine hearts: evidence for two different arrhythmogenic mechanisms. Circ Res. 1980; 47:151-165.
37. Duo GS, Hoff P, Kupersmith J. Repolarization interactions between cardiac segments of varying action potential duration. Am Heart J. 1989; 117:854-861.
38. Kupersmith J, Li ZY, Maldonado C. Marked action potential prolongation as a source of injury current leading to border zone arrhythmogenesis. Am Heart J. 1994;127:1543-1553.
39. Chen J, Xue Y, Eto K, Ni C, Hashimoto K. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. J Cardiovasc Pharmacol. 1996;28:576-584.
40. Picard S, Rouet R, Flais F, Ducouret P, Babatasi G, Khayat A, Potier JC, Bricard H, Gérard JL. Proarrhythmic and antiarrhythmic effects of bupivacaine in an in vitro model of myocardial ischemia and reperfusion. Anesthesiology. 1998;88:1318-1329.
41. Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli M, Crawford DM, Friedrich T, Roden DM. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol. 1995;6: 687-699.